Investigational drug · Phase 2
BBT-877
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Idiopathic Pulmonary Fibrosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 1, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "BBT-877"
First trial start
2023
Apr 12, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BBT-877", any sponsor or status.
Conditions studied
As listed on its trial records.
- Idiopathic Pulmonary Fibrosis
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "BBT-877" as an intervention, largest first.
- To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPFPivotal-lookingCompleted
Bridge Biotherapeutics, Inc.Industry
NCT05483907 · 129 participants · Start Apr 12, 2023 · Primary completion Jan 26, 2025
Drug: BBT-877; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Phoenix, Arizona; Tucson, Arizona; Los Angeles, California · 44 sites in all
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy SubjectsCompleted
Bridge Biotherapeutics, Inc.Industry
NCT03830125 · 88 participants · Start Feb 13, 2019 · Primary completion Nov 24, 2019
Drug: BBT-877, Single dose; Placebo group and 1 more · For: Idiopathic Pulmonary Fibrosis
Sites: Lincoln, Nebraska
Bridge Biotherapeutics, Inc.Industry
NCT04138836 · 48 participants · Start Sep 17, 2019 · Primary completion Nov 4, 2019
Drug: BBT-877; Midazolam and 2 more · For: Healthy Participants
Sites: Lincoln, Nebraska
Bridge Biotherapeutics, Inc.Industry
NCT04138849 · 24 participants · Start Oct 1, 2019 · Primary completion Oct 25, 2019
Drug: BBT-877 single dose; Placebo single dose · For: Healthy Participants
Sites: Cypress, California
Newest research
PubMed records naming it or its code names, newest first.
- Phase 2 study design and analysis approach for BBT-877: an autotaxin inhibitor targeting idiopathic pulmonary fibrosis.
Maher T, Song JW, Kramer MR, et al. · BMJ Open Respir Res 2025
- Autotaxin inhibition attenuates the aortic valve calcification by suppressing inflammation-driven fibro-calcific remodeling of valvular interstitial cells.
Yoon D, Choi B, Kim JE, et al. · BMC Med 2024
- BBT-877, a Novel Autotaxin Inhibitor, Abrogates Drug Resistance in Epithelial Ovarian Cancer Stem Cells.
Kim JS, Shin MJ, Lee SY, et al. · Anticancer Res 2024
- Effect of BBT-877, a novel inhibitor of ATX, on a mouse model of type 1 diabetic nephropathy.
Lee JH, Khin PP, Lee G, et al. · Aging (Albany NY) 2022
- Nucleotide pyrophosphatase/phosphodiesterases (NPPs) including NPP1 and NPP2/ ATX as important drug targets: A patent review (2015-2020).
Bano S, Al-Rashida M, Alharthy RD, et al. · Expert Opin Ther Pat 2022
- Design and Development of Autotaxin Inhibitors.
Jia Y, Li Y, Xu XD, et al. · Pharmaceuticals (Basel) 2021
Also in development for Idiopathic Pulmonary Fibrosis
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- Inhaled TreprostinilLIQ861 Inhaled Treprostinil, Inhaled prostacyclinPhase 35 trials
United Therapeutics · Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- BMS-986278AdmilparantPhase 33 trials
Bristol Myers Squibb · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
- HEC585Phase 33 trials
Sunshine Lake Pharma Co., Ltd. · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF), Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- BI 1015550Phase 32 trials
Boehringer Ingelheim · Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis
- DeupirfenidonePhase 32 trials
PureTech · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- INS018_055Phase 32 trials
InSilico Medicine Hong Kong Limited · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- REGEND001Phase 32 trials
Regend Therapeutics · COPD (Chronic Obstructive Pulmonary Disease), Idiopathic Pulmonary Fibrosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.